Skip to Main Content

The Editas Medicine Mission

Our mission is to translate the power and potential of genome editing into a broad class of CRISPR-based medicines that transform lives of people living with serious diseases.

What We’re Working On

We’re using CRISPR, a powerful genome editing technology to develop new genomic medicines. We are researching and developing both in vivo medicines, which edit genes inside the body, and ex vivo engineered cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients.

Dive into our work

Download

CRISPR has the potential to change outcomes within a broad range of diseases. Right now, we’re concentrating our efforts on 3 major therapeutic areas.

Ocular diseases

Leber Congenital Amaurosis 10 (LCA10), Usher syndrome 2A, retinitis pigmentosa

Blood diseases

Sickle cell disease, Beta-thalassemia

Cancer

Developing both autologous and allogeneic engineered cell medicines for the treatment of solid tumors and blood cancers


Executive Leadership

  • Cynthia Collins,

    President and Chief Executive Officer

  • A headshot of Cindy Collins
  • Cynthia (Cindy) Collins is President and Chief Executive Officer of Editas Medicine and a member of its Board of Directors.

    Cindy is a recognized leader in gene and cell medicines, molecular diagnostics, life sciences, and therapeutics. Most recently, Cindy served as CEO of Human Longevity, Inc. Prior, she served as CEO/GM of General Electric’s Healthcare Life Sciences’ Cell Therapy and Lab Businesses, and CEO of Clarient Diagnostics, Inc. Cindy also served as President and CEO of GenVec, Inc., a publicly traded vaccine and gene therapy company, and before that, she served as Group Vice President, Cellular Analysis, at Beckman Coulter with responsibility for its hematology, flow cytometry, and hemostasis businesses. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals, Inc.

    Earlier in her career, Cindy served as President of Clinical Micro Sensors, Inc., a wholly owned molecular diagnostic subsidiary of Motorola. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President and General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent 6 years in various operating roles.

    Cindy received her BS degree in Microbiology from the University of Illinois, Urbana, and her MBA from the University of Chicago Booth School of Business. She is a member of the board of directors for the Alliance for Regenerative Medicine (ARM) and ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, Inc. DermTech, Inc., and Biocare Medical, LLC.

  • Charles Albright, Ph.D.,

    Executive Vice President and Chief Scientific Officer

  • A headshot of Charles Albright.
  • Charles (Charlie) Albright is Executive Vice President and Chief Scientific Officer of Editas Medicine. He joined Editas Medicine in August 2016 and is responsible for leading the research team that is translating the promise of genome editing into a broad class of transformative genomic medicines.

    Charlie brings more than 25 years of life sciences industry and academic leadership experience to this role. Throughout his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology, and inflammation.

    Before joining Editas Medicine, Charlie spent 14 years at Bristol-Myers Squibb in scientific leadership roles in neuroscience biology. Most recently, he served as Vice President of Genetically-defined Diseases and Genomics. Prior to Bristol-Myers Squibb, Charlie held positions at Incyte Corporation and DuPont Pharmaceuticals and was an assistant professor of biochemistry at Vanderbilt University.

    Charlie earned a BS in chemical engineering and a Ph.D. in biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.

  • Gad Berdugo,

    Chief Business Officer

  • Gad is Chief Business Officer of Editas Medicine. He joined Editas Medicine in July 2020 and oversees business and corporate development, alliance management, and strategy imperatives.

    Gad brings more than 25 years of biotech corporate & business development, strategy, and financial experience. Before joining Editas Medicine, Gad served as CEO of EpiVax Oncology, Inc., a precision cancer immunotherapy company, which he co-Founded in 2017.

    Prior to EpiVax Oncology, Gad held several executive-level positions for life science companies including serving as CFO at Nasdaq listed Immune Pharmaceuticals; Managing Director and Head of Life Sciences at Tegris, a New York based advisory boutique where he led several cross-border M&As and strategic alliances mandates; Founder and Managing Partner of the Explorium Global Healthcare Fund, providing growth capital to emerging biotech companies; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group, where he and his team were responsible for managing $13 billion of investments within the global pharma and biotech sectors.

    Earlier in his career, Gad also served as a Director of Global Business Development within Baxter Healthcare’s $2 billion biopharma group, where he structured, negotiated and concluded acquisitions and strategic alliances with biotech companies, accessing recombinant therapeutic proteins in the fields of immunology, hematology and cancer. He also launched Baxter’s cancer cell-based immunotherapy business unit in France. Gad started his career at Abbott Laboratories.

    Gad currently serves on the board of directors of Genome Profiling, an epigenetic cancer biomarker company. He received his MBA from H.E.C. School of Management in Paris (exchange at Kellogg, Northwestern), his MSc in Biochemical Engineering from University College London, and his BSc with Honors in Biotechnology from Imperial College London.

  • Clare Carmichael,

    Chief Human Resources Officer

  • Clare is Chief Human Resources Officer of Editas Medicine. She joined Editas Medicine in April 2020 and oversees human resources and corporate communications and is responsible for developing and implementing the strategic Human Resources vision in support of the overall goals and mission of the Company.

    Clare brings more than 30 years of Human Resources experience to this role. Before joining Editas Medicine, Clare spent the past two years as CHRO of Wave Life Sciences, a clinical stage genetics medicine company. Prior to Wave, Clare held executive-level human resources positions for several multinational companies across the biotechnology, pharmaceutical, and financial services industries including serving as EVP and CHRO for Alexion Pharmaceuticals, Inc., CHRO of Watson Pharmaceuticals; CHRO of Eyetech Pharmaceuticals; and HR leadership positions at Schering-Plough Corporation, Pharmacia Corporations, and The CIT Group.

    Throughout her career, Clare has provided change-management thought leadership to drive global business and talent agendas in support of rapid growth, successful mergers and integrations, as well as new business and geographic expansions.

    Clare received a Bachelor of Arts in Psychology from Rider University and is a certified professional coach, team performance coach, and strengths coach.

  • Harry Gill,

    Senior Vice President, Operations

  • Harry is Senior Vice President, Operations of Editas Medicine. He joined Editas Medicine in September 2019 as interim Head of Operations and was named Senior Vice President, Operations in January 2020.

    Harry brings more than 30 years of life sciences experience to this role. Throughout his career, Harry has held leadership roles in quality, plant operations, technical services, and operational excellence.

    Harry served as Senior Vice President of Quality and Continuous Improvement at Patheon pharmaceuticals (now ThermoFisher Scientific). Earlier in his career, Harry held various positions at Wyeth (now Pfizer Pharmaceuticals) and Baxter Healthcare Corporation. In addition, he has eight years of international experience, holding manufacturing operations positions in Asia and Puerto Rico.

    Harry received a BS degree in biology from Milligan College and a MS in microbiology from East Tennessee State University.

  • Michelle Robertson,

    Chief Financial Officer

  • Michelle is Chief Financial Officer of Editas Medicine. She joined Editas Medicine in January 2020 and oversees the finance, investor relations, and information technology teams and activities.

    Prior to joining Editas Medicine, Michelle served as Chief Financial Officer of Momenta Pharmaceuticals, Inc. She joined Momenta as Vice President, Financial Planning and Analysis. Prior to joining Momenta, Michelle was Vice President, Oncology Finance for Baxalta, Inc. (which was acquired by Shire PLC in 2016) following its spin-out from Baxter International in July 2015. Before that, Michelle served as head of Financial Planning and Analysis and Operations at Ironwood Pharmaceuticals, and, prior to that, she held various leadership positions in the Oncology and Biosurgery divisions with Finance and Commercial Operations, focusing on financial analysis for business development, acquisition integrations, and divestitures at Genzyme Corporation.

    Michelle received her BS in Finance from Bentley University.

  • Charlene Stern, Ph.D., J.D.,

    Senior Vice President and Chief Legal Officer

  • A headshot of Charlene Stern.
  • Charlene was part of the team that launched Editas Medicine in 2013. As Chief Legal Officer, she oversees and manages all legal matters, including corporate governance, securities compliance and SEC reporting, partnering and licensing transactions, financings, and intellectual property strategy. She also serves as Editas Medicine’s Corporate Secretary. Prior to Editas Medicine, Charlene was senior patent counsel at AVEO Oncology, where she was responsible for developing and executing AVEO’s intellectual property strategy. Earlier in her career, she was a senior attorney in the Boston office of Goodwin LLP and a patent agent at Foley Hoag LLP. Before beginning her legal career, Charlene was an American Cancer Society post-doctoral fellow at Dana-Farber Cancer Institute. She received her J.D. from Suffolk University Law School, a Ph.D. in cell and molecular biology from Yale University, and an A.B. in biochemistry from Mount Holyoke College.

Board of Directors

James (Jim) Mullen joined the Editas Medicine Board of Directors as Chairman in March 2018. Jim is a biotech leader with more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher) in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham.

Jim also serves on the Board of Directors of Thermo Fisher and Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.

Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

Cynthia (Cindy) Collins is President and Chief Executive Officer of Editas Medicine.

Cindy is a recognized leader in gene and cell medicines, molecular diagnostics, life sciences, and therapeutics. Most recently, Cindy served as CEO of Human Longevity, Inc. Prior, she served as CEO/GM of General Electric’s Healthcare Life Sciences’ Cell Therapy and Lab Businesses, and CEO of Clarient Diagnostics, Inc. Cindy also served as President and CEO of GenVec, Inc., a publicly traded vaccine and gene therapy company, and before that, she served as Group Vice President, Cellular Analysis, at Beckman Coulter with responsibility for its hematology, flow cytometry, and hemostasis businesses. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals, Inc.

Earlier in her career, Cindy served as President of Clinical Micro Sensors, Inc., a wholly owned molecular diagnostic subsidiary of Motorola. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President and General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent 6 years in various operating roles.

Cindy received her BS degree in Microbiology from the University of Illinois, Urbana, and her MBA from the University of Chicago Booth School of Business. She is a member of the board of directors for the Alliance for Regenerative Medicine (ARM) and ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, Inc. DermTech, Inc., and Biocare Medical, LLC.

Andrew joined the Editas Medicine Board of Directors in May 2017 with more than 20 years of experience in a range of strategic and operating business roles, including more than 15 years in the biotech industry. Andrew currently serves as President, a member of the Board of Directors, and incoming Chief Executive Officer of C4 Therapeutics (C4T). Prior to C4T, Andrew served as Chief Financial Officer at Agios Pharmaceuticals, Inc., and as its Head of Corporate Development. Earlier in his career, Andrew served as President and Chief Executive Officer of BIND Therapeutics, Inc., and as Chief Financial Officer at Avila Therapeutics, Inc., until its acquisition by Celgene Corporation. He also held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team.

Andrew holds an MBA from the Tuck School at Dartmouth College and a BA in Economics from the University of Pennsylvania.

Jessica is a scientist and business leader with more than 2 decades of experience in the medical and healthcare fields. She joined the Editas Medicine Board of Directors in February 2018. Jessica serves as an Independent Director on the Board of Directors of Insulet Corporation and of Radius Health, Inc., and is a trustee of the Joslin Diabetes Center. In addition, she is a strategic advisor and investor in start-up healthcare firms, including serving as a strategic advisor to and as the former independent director of rEVO Biologics.

Jessica is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical-device, and consumer industries. She also held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing.

Jessica earned a BS from Yale College, an MBA from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in neuroscience/biochemistry from the Rockefeller University.

David joined the Editas Medicine Board of Directors in February 2019. He is a hematologist/oncologist and an expert in stem-cell biology and blood malignancies. He is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. He is chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. David has published more than 350 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem-cell function.

David is the recipient of numerous honors, including elected membership of the National Academy of Medicine and the American Academy of Arts and Sciences, a fellowship at the American College of Physicians and at the American Association for the Advancement of Science, and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Wellcome Fund, and the Leukemia and Lymphoma Society. He has served on the board of scientific counselors for the National Cancer Institute; the board of external experts for the National Heart, Lung and Blood Institute; the board of directors of the International Society for Stem Cell Research; and is an affiliate member of the Broad Institute of Harvard and MIT. He also serves on multiple editorial boards, scientific advisory boards, and corporate boards, the latter including Agios and Magenta Therapeutics. He is a scientific founder of Fate Therapeutics, Inc., and Magenta Therapeutics, Inc., and serves as a director on Magenta’s board of directors. David also serves on the board of directors of LifeVault Bio and Clear Creek Bio, Inc.

David is a graduate of Bucknell University (B.A.) and Case Western Reserve University (M.D.) with honorary degrees awarded from Harvard University (A.M.), Bucknell University (Sc.D.), Case Western Reserve University (Sc.D.) and Lund University in Sweden (M.D.). He serves as a Visiting Scholar to Pembroke College, University of Cambridge, U.K.

Akshay joined the Editas Medicine Board of Directors in July 2016. He has served as Alnylam’s President of Research and Development since March 2018. He joined Alnylam in January 2006 as VP, Clinical Research, and since that time has held positions of increasing responsibility including SVP, Clinical Research; EVP, Research and Development; and Chief Medical Officer, before assuming his current role. From December 1998 through 2005, he held various positions in medical research at Biogen.

Akshay received his M.D. from the University of Wales College of Medicine, UK, and his Ph.D. from the University of London, UK, in molecular immunology. He is also a Fellow of the Royal College of Physicians, UK. He serves on the board of directors of Scholar Rock, Inc., and previously served on the board of directors of Visterra, Inc.

Our Scientific Founders

Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation

Feng joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. He is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Feng is a Searle Scholar and has received both a Director’s Transformative Research Award and a Director’s Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.

Feng holds an AB degree in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.

Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering

George is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the US Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. George helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. George has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.

George holds a Ph.D. in biochemistry and molecular biology from Harvard University and a BA in zoology and chemistry from Duke University.

Keith currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.

Keith has been a pioneer in the development of important technologies for targeted gene editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.

Keith holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School, and an AB degree in biochemical sciences from Harvard College.

David is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT). His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and gene editing. David’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the US government on matters of science and technology. He is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation Faculty Early Career Development Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award, and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. David was named to the Popular Science “Brilliant 10” for young scientists in the US, as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology. His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.

David holds a BA degree in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley.